These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34105341)

  • 1. TOOLBOX: Strep‑Tagged nano‑assemblies of antibody‑drug‑conjugates (ADC) for modular and conditional cancer drugging.
    Tremante E; Sibilio L; Centola F; Knutti N; Holzapfel G; Manni I; Allegretti M; Lombardi P; Salvo G; Cecchetelli L; Friedrich K; Bertram J; Giacomini P
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 34105341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Corrigendum] TOOLBOX: Strep‑Tagged nano‑assemblies of antibody‑drug‑conjugates (ADC) for modular and conditional cancer drugging.
    Tremante E; Sibilio L; Centola F; Knutti N; Holzapfel G; Manni I; Allegretti M; Lombardi P; Salvo G; Cecchetelli L; Friedrich K; Bertram J; Giacomini P
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34261292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation.
    Stefan N; Gébleux R; Waldmeier L; Hell T; Escher M; Wolter FI; Grawunder U; Beerli RR
    Mol Cancer Ther; 2017 May; 16(5):879-892. PubMed ID: 28258164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes.
    Drake PM; Albers AE; Baker J; Banas S; Barfield RM; Bhat AS; de Hart GW; Garofalo AW; Holder P; Jones LC; Kudirka R; McFarland J; Zmolek W; Rabuka D
    Bioconjug Chem; 2014 Jul; 25(7):1331-41. PubMed ID: 24924618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy.
    Kang JC; Sun W; Khare P; Karimi M; Wang X; Shen Y; Ober RJ; Ward ES
    Nat Biotechnol; 2019 May; 37(5):523-526. PubMed ID: 30936563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers.
    van der Lee MM; Groothuis PG; Ubink R; van der Vleuten MA; van Achterberg TA; Loosveld EM; Damming D; Jacobs DC; Rouwette M; Egging DF; van den Dobbelsteen D; Beusker PH; Goedings P; Verheijden GF; Lemmens JM; Timmers M; Dokter WH
    Mol Cancer Ther; 2015 Mar; 14(3):692-703. PubMed ID: 25589493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
    Ogitani Y; Hagihara K; Oitate M; Naito H; Agatsuma T
    Cancer Sci; 2016 Jul; 107(7):1039-46. PubMed ID: 27166974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers.
    Skidmore L; Sakamuri S; Knudsen NA; Hewet AG; Milutinovic S; Barkho W; Biroc SL; Kirtley J; Marsden R; Storey K; Lopez I; Yu W; Fang SY; Yao S; Gu Y; Tian F
    Mol Cancer Ther; 2020 Sep; 19(9):1833-1843. PubMed ID: 32669315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.
    Loganzo F; Tan X; Sung M; Jin G; Myers JS; Melamud E; Wang F; Diesl V; Follettie MT; Musto S; Lam MH; Hu W; Charati MB; Khandke K; Kim KS; Cinque M; Lucas J; Graziani E; Maderna A; O'Donnell CJ; Arndt KT; Gerber HP
    Mol Cancer Ther; 2015 Apr; 14(4):952-63. PubMed ID: 25646013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-Specific Antibody Drug Conjugates Using Streamlined Expressed Protein Ligation.
    Frutos S; Hernández JL; Otero A; Calvis C; Adan J; Mitjans F; Vila-Perelló M
    Bioconjug Chem; 2018 Nov; 29(11):3503-3508. PubMed ID: 30346741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
    Iwata TN; Ishii C; Ishida S; Ogitani Y; Wada T; Agatsuma T
    Mol Cancer Ther; 2018 Jul; 17(7):1494-1503. PubMed ID: 29703841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
    Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
    Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction and evaluation of pH-sensitive immunoliposomes for enhanced delivery of anticancer drug to ErbB2 over-expressing breast cancer cells.
    Li T; Amari T; Semba K; Yamamoto T; Takeoka S
    Nanomedicine; 2017 Apr; 13(3):1219-1227. PubMed ID: 27965166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
    Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
    Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MI130004, a Novel Antibody-Drug Conjugate Combining Trastuzumab with a Molecule of Marine Origin, Shows Outstanding
    Avilés P; Domínguez JM; Guillén MJ; Muñoz-Alonso MJ; Mateo C; Rodriguez-Acebes R; Molina-Guijarro JM; Francesch A; Martínez-Leal JF; Munt S; Galmarini CM; Cuevas C
    Mol Cancer Ther; 2018 Apr; 17(4):786-794. PubMed ID: 29440297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.